Methods and compositions using fgf23 fusion polypeptides

作者: David Jonathan Glass , Shou-Ih Hu

DOI:

关键词:

摘要: The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions metabolic disorders. fusion polypeptides of the include FGF23 an active fragment thereof. In one embodiment, polypeptide comprises (a) a comprising fibroblast growth factor 23 (FGF23), functionally variant derivative thereof, wherein has mutation at more positions Q 156, C206 C244; (b) either modified Fc having decreased affinity Fc-gamma-receptor and/or increased serum half-life, least extracellular subdomain Klotho protein, thereof; and, optionally (c) linker. proteins are useful in treatment prevention variety another FGF (such as FGF23), fragment, various embodiments polypeptides, mutations which decrease aggregation protease-mediated cleavage.

参考文章(73)
John L.R. Rubenstein, Maike Sander, Roger A. Pedersen, Michael S. German, Juanito J. Meneses, Lori Sussel, Dennis J. Hartigan-O'Connor, NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity ,(1997)
Victor F. Smolen, LuAnn Ball, Drug product design and performance Wiley. ,(1984)
Bradford A. Jameson, Robert K. Campbell, Scott C. Chappel, DNA encoding a hybrid heterodimeric protein ,(1997)
Makoto Kuroo, Youichi Nabeshima, Susumu Sekine, Akihiro Iida, Novel peptide, novel dna, and novel antibody ,(1997)
Sue C. Bodine, David J. Glass, Novel nucleic acid and polypeptide molecules ,(2002)
Liselotte Bjerre Knudsen, Søren Bregenholt, Carsten Foged Godtfredsen, Richard David Carr, Jacob Sten Petersen, Inhibition of beta cell degeneration ,(2000)
Jason Pinkstaff, Kristin S Eaton, Anna-Maria A Hays Putnam, Modified fgf-23 polypeptides and their uses ,(2009)